Classification
Product TypeIngredient
Product FormBotanical extract (typically powder or liquid concentrate)
Industry PositionFood / nutraceutical / cosmetic ingredient (botanical extract)
Market
Pomegranate extract in Switzerland is primarily an imported botanical ingredient used in food supplements, functional food and beverage formulations, and cosmetics. Domestic primary production of pomegranate for extract manufacture is not significant, so market availability depends on foreign extraction supply and Swiss importer quality-release practices. The main market-access sensitivity is regulatory classification and compliant labeling/claims (food/food supplement versus medicinal positioning), rather than seasonal domestic harvest. Buyers typically emphasize standardized active-marker specifications (e.g., polyphenol-related measures) and contaminant control to meet Swiss market expectations.
Market RoleImport-dependent ingredient and consumer market (net importer)
Domestic RoleDemand is driven by Swiss manufacturers/brand owners and importers distributing botanical extracts into dietary supplements, functional products, and personal-care formulations.
Specification
Physical Attributes- Sold as a dry powder extract or liquid concentrate; appearance and color can vary by extraction method and carrier ingredients
- Hygroscopic powders may require moisture-barrier packaging to maintain flowability and potency
Compositional Metrics- Supplier specifications commonly include standardization and/or assay reporting for polyphenol-related markers (method- and supplier-dependent) supported by a Certificate of Analysis (COA)
Grades- Food-grade (for foods/food supplements) versus cosmetic-grade (for personal-care), aligned to intended use and documentation package
Supply Chain
Value Chain- Source-country pomegranate raw material (often peel/juice streams) → extraction/standardization facility → bulk packaging → import into Switzerland → QC/quality release by Swiss importer/manufacturer → formulation into supplements/foods/cosmetics → finished-goods distribution
Temperature- Typically shipped and stored under ambient, dry conditions; protection from heat, light, and moisture is emphasized to preserve extract quality
Shelf Life- Shelf-life is strongly dependent on moisture control and packaging integrity; Swiss buyers commonly rely on supplier COA/specification plus incoming QC to manage lot-to-lot consistency
Freight IntensityLow
Transport ModeMultimodal
Risks
Regulatory Compliance HighIn Switzerland, pomegranate extract can face market-access disruption if its presentation, dosage form, or claims push it into a non-compliant category (e.g., medicinal positioning without the appropriate pathway) or if labeling/claims are not acceptable for the intended Swiss market category (food/food supplement/cosmetic). This can result in delisting, enforcement action, or product withdrawal.Lock the intended Swiss product category early (food/food supplement/cosmetic vs medicinal), align labeling and claims accordingly, and maintain a complete technical dossier for importer quality release (spec, COA, composition, and safety documentation).
Food Safety MediumBecause plant extracts concentrate the source material, non-compliance with pesticide-residue and contaminant expectations (e.g., heavy metals or process-related contaminants) can trigger rejection, recall, or loss of buyer approval in Switzerland.Use approved suppliers with traceable lots; require routine third-party testing aligned to intended use; and verify each lot against the Swiss importer’s specification before release.
Documentation Gap MediumIncomplete documentation (missing COA/spec, unclear carrier ingredients, or weak traceability statements) can delay Swiss quality release and block downstream use in supplements or cosmetics even if the material is physically available.Standardize a Swiss-ready documentation pack per lot (COA + spec + composition/carrier disclosure + traceability statement; SDS when applicable) and run a pre-shipment document check.
Quality Integrity LowLot-to-lot variability and possible dilution/standardization differences across suppliers can lead to inconsistent active-marker assays and performance in Swiss finished products, creating commercial and compliance risk if label declarations cannot be supported.Specify analytical methods and acceptance criteria in supplier agreements, and implement incoming QC verification for each lot used in Swiss production.
FAQ
Which Swiss authorities are most relevant when importing and selling pomegranate extract products?For products marketed as foods or food supplements, the key reference authority is the Swiss Federal Food Safety and Veterinary Office (FSVO/BLV) and the associated Swiss food-law enforcement system. If the product is positioned as a therapeutic/medicinal product (e.g., through disease-related claims), Swissmedic becomes the relevant authority for therapeutic products. Customs clearance is handled via the Federal Office for Customs and Border Security (FOCBS/BAZG).
What documentation is commonly needed to clear and quality-release pomegranate extract for the Swiss market?Swiss importers typically need standard shipping documents (commercial invoice, packing list, and a transport document) plus an ingredient documentation pack that supports quality release and downstream compliance, especially a lot-specific Certificate of Analysis (COA) and a product specification sheet (including composition and any carrier ingredients). A Certificate of Origin is commonly needed when claiming preferential origin, and an SDS is often requested when handled as a chemical/industrial input or by downstream manufacturers.
What is the most common deal-breaker risk for pomegranate extract commercialization in Switzerland?The main deal-breaker is regulatory and claims non-compliance: if the Swiss-market presentation and claims do not match the correct category (food/food supplement/cosmetic versus medicinal positioning), the product can be stopped through enforcement actions such as delisting or withdrawal. Aligning category, labeling, and claims with FSVO/BLV expectations (and Swissmedic where medicinal positioning is involved) is critical.